Dyadic International (NasdaqCM:DYAI) Q4 2025 Earnings call March 25, 2026 05:00 PM ET Company ParticipantsJoe Hazelton - President and COOMark Emalfarb - CEOPing Rawson - CFOTony Bowers - DirectorConference Call ParticipantsJohn Vandermosten - Senior AnalystMatthew Hewitt - Senior Research AnalystNone - AnalystOperatorI would now like to turn the call over to Mrs. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.Ping RawsonThank you, operator. Good evening, and welcome everyone to Dyadic's Ful ...

Dyadic International (NasdaqCM:DYAI) Q4 2025 Earnings call March 25, 2026 05:00 PM ET Company ParticipantsJoe Hazelton - President and COOMark Emalfarb - CEOPing Rawson - CFOTony Bowers - DirectorConference Call ParticipantsJohn Vandermosten - Senior AnalystMatthew Hewitt - Senior Research AnalystNone - AnalystOperatorI would now like to turn the call over to Mrs. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.Ping RawsonThank you, operator. Good evening, and welcome everyone to Dyadic's ful ...

Dyadic International (NasdaqCM:DYAI) Q4 2025 Earnings call March 25, 2026 05:00 PM ET Speaker5I would now like to turn the call over to Mrs. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.Speaker6Thank you, operator. Good evening, and welcome everyone to Dyadic's full year 2025 conference call. I hope you have had the opportunity to review Dyadic's press releases announcing financial results for the year ended December 31, 2025. You may access our release and Form 10-K under the investors se ...

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic’s recombinant DNase I and transferrin f ...

Exhibit 99.1 DYADIC ANNOUNCES 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS JUPITER, Fla., March 25, 2026 — Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), d/b/a, Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for 2025 along with significant corporate achievements. "During 2025 and into early 2026, w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission file number: 001-32513 DYADIC INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 45-0486747 (State or other jurisdict ...

JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer (“OEM”) distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices (“IBT”), a life sciences reagent manuf ...

Summary of Dyadic International Conference Call Company Overview - **Company**: Dyadic International (NasdaqCM: DYAI) - **Industry**: Life Sciences, specifically focusing on bioengineering proteins for therapeutic and non-therapeutic applications Key Points and Arguments 1. **Transition to Commercialization**: Dyadic has shifted from an R&D stage company to a commercial organization over the past three years, aiming to generate revenue through product launches [2][5][31] 2. **Rebranding and Focus**: The company rebranded to Dyadic Applied BioSolutions and is now focusing on product technology rather than platform technology, with an emphasis on commercializing products in shorter timeframes [4][31] 3. **Product Portfolio Development**: Dyadic has developed a portfolio of products that require less investment and time to commercialize, including the Dapibus platform for food and nutrition [4][6][10] 4. **Revenue Generation Strategy**: The revenue strategy is based on "buy, brand, and build," allowing direct sales, OEM white label sales, and licensing of strains to partners [11][13] 5. **Market Focus**: The company is targeting large and growing markets in life sciences, food and nutrition, and bioindustrial sectors, with specific advantages in producing non-animal proteins and enzymes at lower costs [13][14][15] 6. **Key Product Launches**: Dyadic has launched several products, including DNase I and AlbuFree DX, and is preparing to launch transferrin and growth factors [18][21][22] 7. **Partnerships**: Strategic partnerships with companies like Proliant Health and Biologicals and Inzymes are crucial for product launches and revenue generation [7][23][24] 8. **Pipeline and Future Products**: The company has a robust pipeline with upcoming products in both life sciences and food sectors, including human and bovine alpha-lactalbumin [21][26] 9. **Financial Expectations**: Initial revenues are expected from product sales and partnerships, with a goal to achieve a steady revenue run rate by layering product and partnership revenues [27][28][33] 10. **Regulatory Advantages**: Non-therapeutic products do not require FDA review, allowing for quicker commercialization compared to traditional therapeutic products [32] Additional Important Content - **CRISPR Technology**: The integration of CRISPR technology enhances the ability to optimize protein production, opening new product categories [35] - **Legacy Programs**: Ongoing legacy R&D programs are fully funded and will not detract from current revenue-generating efforts, serving as potential future revenue sources [30][31] - **Market Perception**: There is a belief that the market underestimates Dyadic's earning potential for 2026 and 2027, as the company is now positioned to generate significant revenues from its products [36][37] - **Strategic Shift**: The focus has shifted from licensing technology to generating direct revenues through product sales, indicating a more proactive approach to market engagement [38] This summary encapsulates the key insights from the Dyadic International conference call, highlighting the company's strategic direction, product development, and market positioning.

JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the ye ...

Core Insights - Dyadic Applied BioSolutions and Fermbox Bio have launched the first commercial product, animal-origin-free Recombinant DNase I, marking a significant step in their collaboration and commercial product expansion [1][3][4] Group 1: Product Launch and Development - Recombinant DNase I (RNase-free) is produced using Dyadic's high-yield fungal microbial expression platforms and Fermbox Bio's biomanufacturing capabilities, currently available in research grade with a cGMP-grade version in development [2][6] - The enzyme is crucial for nucleic-acid clean-up and sample preparation, supporting RNA integrity in various applications including biotechnology and molecular diagnostics [3][5] - This product is the first in a series of recombinant enzymes and proteins planned for commercialization throughout 2026 [4] Group 2: Future Product Pipeline - Planned pipeline products include recombinant α-lactalbumin, recombinant transferrin, recombinant human FGF-2, and recombinant human lactoferrin, targeting high-demand segments in cell culture media and molecular biology reagents [5] - These products will support applications in cell and gene therapy, vaccine manufacturing, and advanced biologics development [5] Group 3: Collaboration Framework - Under the collaboration, Dyadic provides its expression platforms and production strains, while Fermbox Bio focuses on downstream process development and manufacturing [6] - The companies aim for global commercialization to serve research and biomanufacturing customers [6] Group 4: Company Background - Dyadic Applied BioSolutions specializes in producing recombinant proteins for life sciences, food, and bio-industrial markets, utilizing proprietary microbial platforms [7] - Fermbox Bio develops sustainable bio-based products through precision fermentation and advanced biotechnology [8]